Neurocrine Biosciences (NBIX) Tops Q2 EPS by 69c ; Offers Guidance
Tweet
Share
E-mail
Get Alerts NBIX Hot Sheet
Price: $143.96 -1.55%
Revenue Growth %: +30.8%
Financial Fact:
Total operating expenses: 38.44M
Today's EPS Names:
MLKN, KBH, WOR, More
Revenue Growth %: +30.8%
Financial Fact:
Total operating expenses: 38.44M
Today's EPS Names:
MLKN, KBH, WOR, More
Join SI Premium – FREE
Neurocrine Biosciences (NASDAQ: NBIX) reported Q2 EPS of $1.65, $0.69 better than the analyst estimate of $0.96. Revenue for the quarter came in at $687.5 million versus the consensus estimate of $653.32 million.
GUIDANCE:
Neurocrine Biosciences sees FY2025 revenue of $2.5-2.55 billion, versus the consensus of $2.68 billion.
For earnings history and earnings-related data on Neurocrine Biosciences (NBIX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Deutsche Bank Upgrades Danone SA (BN:FP) (DANOY) to Hold
- Deutsche Bank Upgrades Danone SA (BN:FP) (DANOY) to Hold
- Goldman Sachs Upgrades SK Innovation Co Ltd (096770:KS) to Neutral
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
